United States· US:0074-7094_392c0320-ca25-423a-9bc1-d06f6badab07
Qulipta
A atogepant product containing atogepant, registered in United States by AbbVie Inc.. The same ATC class is registered in 16 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Atogepant is registered in 16 of 19 countries.
Countries holding a registration under ATC N02CD07 (atogepant), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 11 of them publish a price we can compare per daily dose
Atogepant · ATC N02CD07
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of atogepant costs, country by country.
Normalised to the WHO defined daily dose (60 mg), so markets compare like for like.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Atogepant · price per daily dose (60 mg)
USD · FX 28 Sept 2026
- IT Italy$96.51
- CH Switzerland$95.15
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- ATOGEPANT
- Manufacturer
- AbbVie Inc.
- Country
- United States (US)
- ATC code
- N02CD07
- ATC class
- Atogepant
- Defined daily dose
- 60 mg, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 6
- ndc1100747094044 TABLET in 1 BOTTLE (0074-7094-04)
- ndc11007470943030 TABLET in 1 BOTTLE (0074-7094-30)
- ndc1100747094704 TABLET in 1 BOTTLE (0074-7094-70)
- ndc110074-7094-04
- ndc110074-7094-30
- ndc110074-7094-70
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Atogepant in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaAQUIPTAAbbVie Deutschland GmbH & Co.KG, Ludwigshafen
- SwitzerlandAquipta
- SpainAQUIPTA 60 MG COMPRIMIDOSAbbvie Deutschland Gmbh & Co. Kg
- FinlandAQUIPTAAbbVie Deutschland GmbH&Co.KG
- FranceAQUIPTA 60 mg, compriméABBVIE DEUTSCHLAND (ALLEMAGNE)
- United KingdomAquipta 60mg tabletsAbbVie Ltd
- IrelandAQUIPTA 60 mg tabletsAbbVie Deutschland GmbH & Co. KG
- IcelandAquiptaAbbVie Deutschland GmbH & Co. KG
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Aquipta
- Iceland · Aquipta
- Liechtenstein · Aquipta
- Norway · Aquipta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/730a348a-ff32-4eaf-b647-e07bed0a204e GET /v1/drugs/730a348a-ff32-4eaf-b647-e07bed0a204e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "60",
"substance": "ATOGEPANT",
"productndc": "0074-7094",
"dosage_form": "TABLET",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA215206",
"marketing_category": "NDA"
}See everything about atogepant.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.